Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.
Check source scope before reading a dose
Clofarabine IV injection (Clolar) - selected label sections
Product / population
CLOLAR IV injection: labeled pediatric population ages 1 to 21 with relapsed/refractory ALL after at least two prior regimens. Not a general adult oncology dosing protocol.
Renal method
Creatinine clearance (CrCl), mL/min, as stated in the label; retain the source-specific age and renal-assessment context.
Source revision
12/2019
Retrieved
2026-10-02
Local review status
Selected renal sections summarized locally. Not a complete monograph or independent clinical approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Before use: Clofarabine IV injection (Clolar)
Renal thresholds agree in the selected passages, but source revisions differ (manufacturer 2019; RX 2022). Full current-label reconciliation is pending.
What to reconcile: Confirm the current oncology protocol, exact patient population and label before use. No recommendation is inferred for CrCl <30 or dialysis.
Sanofi / CLOLAR prescribing information · CLOLAR IV injection: labeled pediatric population ages 1 to 21 with relapsed/refractory ALL after at least two prior regimens. Not a general adult oncology dosing protocol.
Renal method: Creatinine clearance (CrCl), mL/min, as stated in the label; retain the source-specific age and renal-assessment context. Source date: 12/2019 Retrieved: 2026-10-02
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Confirm the current oncology protocol, exact patient population and label before use. No recommendation is inferred for CrCl <30 or dialysis.
Dialysis evidence: No dialysis regimen established in selected content
Selected renal sections summarized locally. Not a complete monograph or independent clinical approval.
Renal guidance and important limits
Limits that apply to these rows
Labeled baseline regimen is 52 mg/m2 IV over 2 hours daily for 5 consecutive days. Baseline renal reduction and later toxicity-driven changes are separate decisions.
Monitor renal function and minimize nephrotoxic co-medications during treatment. Oncology protocol review is required.
Source currency limitation: manufacturer page is dated 12/2019, whereas the RX mirror is dated 07/2022. The shared selected renal instructions do not establish that the full older label is current.
Clofarabine IV injection (Clolar) - selected renal instructions
Renal setting
Source-specific action and limits
CrCl 30 to 60 mL/min, including 60
Reduce the starting dose by 50%. This is not a newly calculated patient-specific dose.
CrCl <30 mL/min or dialysis
Insufficient information for a recommended dose. Do not extrapolate the 50% reduction.
Read the retained text before reformatting
Renal setting
Source-specific action and limits
CrCl 30 to 60 mL/min, including 60
Reduce the starting dose by 50%. This is not a newly calculated patient-specific dose.
CrCl <30 mL/min or dialysis
Insufficient information for a recommended dose. Do not extrapolate the 50% reduction.
Labeled baseline regimen is 52 mg/m2 IV over 2 hours daily for 5 consecutive days. Baseline renal reduction and later toxicity-driven changes are separate decisions.
Monitor renal function and minimize nephrotoxic co-medications during treatment. Oncology protocol review is required.
Source currency limitation: manufacturer page is dated 12/2019, whereas the RX mirror is dated 07/2022. The shared selected renal instructions do not establish that the full older label is current.
The official product label and its RX mirror are one underlying evidence family, not two independent clinical validations. Confirm the current exact product label before prescribing.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v6.8. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.